Morinda officinalis oligosaccharides increase serotonin in the brain and ameliorate depression via promoting 5-hydroxytryptophan production in the gut microbiota

Zheng-Wei Zhang,Chun-Sheng Gao,Heng Zhang,Jian Yang,Ya-Ping Wang,Li-Bin Pan,Hang Yu,Chi-Yu He,Hai-Bin Luo,Zhen-Xiong Zhao,Xin-Bo Zhou,Yu-Li Wang,Jie Fu,Pei Han,Yu-Hui Dong,Gang Wang,Song Li,Yan Wang,Jian-Dong Jiang,Wu Zhong
DOI: https://doi.org/10.1016/j.apsb.2022.02.032
IF: 14.903
2022-03-01
Acta Pharmaceutica Sinica B
Abstract:<i>Morinda officinalis</i> oligosaccharides (MOO) are an oral drug approved in China for the treatment of depression in China. However, MOO is hardly absorbed so that their anti-depressant mechanism has not been elucidated. Here, we show that oral MOO acted on tryptophan → 5-hydroxytryptophan (5-HTP) → serotonin (5-HT) metabolic pathway in the gut microbiota. MOO could increase tryptophan hydroxylase levels in the gut microbiota which accelerated 5-HTP production from tryptophan; meanwhile, MOO inhibited 5-hydroxytryptophan decarboxylase activity, thus reduced 5-HT generation, and accumulated 5-HTP. The raised 5-HTP from the gut microbiota was absorbed to the blood, and then passed across the blood-brain barrier to improve 5-HT levels in the brain. Additionally, pentasaccharide, as one of the main components in MOO, exerted the significant anti-depressant effect through a mechanism identical to that of MOO. This study reveals for the first time that MOO can alleviate depression <i>via</i> increasing 5-HTP in the gut microbiota.
pharmacology & pharmacy
What problem does this paper attempt to address?